3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Cisplatin
15
Pemetrexed
12
pembrolizumab
9
Carboplatin
8
Nivolumab
7
Cyclophosphamide
6
Platinum
5
Ipilimumab
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
3
Radiotherapy, Intensity-Modulated
3
Interleukin-2
3
Gemcitabine
3
tremelimumab
2
durvalumab
2
atezolizumab
2
aldesleukin
2
Radiotherapy
2
Radiation
2
Photochemotherapy
2
Pharmaceutical Preparations
2
Methotrexate
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
Cerebral Decortication
2
nintedanib
1
methoxyamine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
cediranib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Blood Component Removal
×
1 year
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled